Strategy for the treatment of acute myelogenous leukemia based on folate receptor β-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid

Blood

Volumn 100, Issue 2, 2002, Pages 594-602

  Pan, Xing Q ^a,b   Zheng, Xuan ^a,b   Shi, Guangfeng ^a,b   Wang, Huaqing ^a,b   Ratnam, Manohar ^a,b   Lee, Robert J ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; DOXORUBICIN; FOLIC ACID; NITROUS ACID; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE PHOSPHODIESTERASE; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DEGLYCOSYLATION; DRUG DELIVERY SYSTEM; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION;

EID: 0037100463     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.2.594     Document Type: Article

References (60)

1. Adult acute myeloid leukaemia: Update on treatment
2. Anthracycllnes in the treatment of cancer: An overview
3. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia
4. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors
5. 2
6. Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells
7. Effect of liposomes on P-glycoprotein function in multidrug resistant cells
8. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer: TLC D-99 Study Group
9. Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia
10. Phase II study of pegylated liposomal doxorubicin: Inactive in recurrent small-cell lung cancer: A Hellenic Cooperative Oncology Group Study
11. Phase II study of liposomal doxorubicin in patients with advanced colorectal cancer
12. Pegylated doxorubicin for primary cutaneous T-cell lymphoma: A report on ten patients with follow-up
13. High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours
14. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer
15. Liposome-encapsulated daunorubicin for PGP-related multidrug resistance
16. Liposome encapsulated daunorubicin doubles anthracycline toxicity in cell lines showing a non-PGP related multidrug resistance
17. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump
18. Immunoliposomes for cancer treatment
19. Anti-HER2 immunoliposomes for targeted drug delivery
20. Complementary DNA for the folate binding protein correctly predicts anchoring to the membrane by glycosyl-phosphatidylinositol
21. Homologous membrane folate binding proteins in human placenta: Cloning and sequence of a cDNA
22. Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity
23. Preferred sites of glycosylphosphatidylinositol modification in folate receptors and constraints in the primary structure of the hydrophobic portion of the signal
24. Folate receptor type γ is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: Protein characterization and cell type specificity
25. Cellular localization of the folate receptor: Potential role in drug toxicity and folate homeostasis
26. Expression of folate receptor type α in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix
27. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues
28. Trophoblast and ovarian cancer antigen LK26: Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein
29. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines: Physiologic and clinical implications
30. Folate-mediated targeting of therapeutic and imaging agents to cancers
31. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis
32. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro
33. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: In vitro studies
34. Receptor-specific delivery of liposomes via folate-PEG-chol
35. Folate receptor type β is neutrophilic lineage marker and is differentially expressed in myeloid leukemia
36. Selective expression of folate receptor β and its possible role in methotrexate transport in synovial macrophages form patients with rheumatoid arthritis
37. Characterization of multiple forms of folate-binding protein from human leukemia cells
38. Purification, properties, and immunological characterization of folate-binding proteins from human leukemia cells
39. Expression and functional characterization of the β-isoform of the folate receptor on CD34+ cells
40. Differentiation-independent retinoid induction of folate receptor type β, a potential tumor target in myeloid leukemia
41. Clustering of GPI-anchored folate receptor independent of both cross-linking and association with caveolin
42. Synthesis and biological evaluation of a fluorescent analogue of folic acid
43. Variant GPI structure in relation to membrane-associated functions of a murine folate receptor
44. Expression of functional folate receptors α and β are related to the number of N-glycosylated sites
45. Colorimetric determination of phospholipids with ammonium ferrothiocyanate
46. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients
47. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin
48. Pharmacological-toxicological expert report-Caelyx™ (Stealth Liposomal Doxorubicin HCl)
49. Cali-cheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines
50. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
51. A magic bullet for cancer: How near and how far?
52. Efficacy of the anti-CD22 recombinant immunotoxins BL22 in chemotherapy-resistant hairy-cell leukemia
53. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
54. -
55. Trends in serum folate after food fortification
56. Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolates
57. Receptor-targeted delivery of liposomes via folate-PEG-chol
58. Boron delivery to a murine lung carcinoma using folate receptor-targeted liposomes
59. A systematic overview of chemotherapy effects in acute myelogenous leukemia
60. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia